HeraMED Limited signed a MOU with the Gold Coast Hospital

HeraMED Limited (ASX: HMD) announced that it had signed a MOU with the Gold Coast Hospital to trial the HeraCARE platform as its new standard of care for their Women, Newborn, and Children Services (WNCS). Initially, a controlled trial of the HeraCARE platform will be undertaken for up to 90 pregnancies for six to nine months to evaluate clinical usability, patient satisfaction, value for money, and economic analysis.

Additionally, HeraMED will collaborate with Gold Coast Health on a clinical implementation study to evaluate various use cases, including acceptability, cost-effectiveness analysis, and clinical results. GCHHS aims to order more licences if the experiment is successful, subject to a proper market scan, value for money evaluation, and clinical outcomes.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com